On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Complex carbohydrates
- Glycocalyx: the cell surface carbohydrate layer
- Cell surface carbohydrate interactions
- Biosynthesis of oligosaccharides
- Many tumor markers are Carbohydrates
- Pathogens infecting by carbohydrate recognition
- Lectins: native carbohydrate-binding proteins
- The selectins are therapeutic targets
- Enhancing carbohydrate-lectin interaction
- Bioactive conformation of glycomimetic 69669a
- Preorganization of the bioactive conformation
- Enhancing binding affinity for E-selectin
- E & P-selectins binding to native ligand PSGL-1
- Glycosylation and sulfation of PSGL-1
- Sulfated drug-like fragment-based library
- GMI-1070 is a pan selectin antagonist
- GMI-1070: pre-clinical models
- Effect of GMI-1070 animal models
- Sickle cell Vaso-Occlusive Crisis (VOC)
- Testing the effects of GMI-1070 on VOC
- GMI-1070 for vaso-occlusive crisis
- Effects of GMI-1070 in sickle cell mice
- GMI-1070 extends survival in sickle cell mice
- GMI-1070- synthesized through convergent steps
- Scale-up chemistry and process development
- Organizations involved in GMI-1070 synthesis
- GMI-1070: phase I clinical trial
- Pharmacokinetics of a single dose of GMI-1070
- Phase 1 healthy volunteers - safety summary
- Clinical trials testing effects of GMI-1070
- GMI-1070: summary
- Validation of the potential of glycomimetic drugs
- Summary
- Scientific contributors
Topics Covered
- Glycobiology as an untapped source of innovative drugs
- Rationally designed selectin antagonists based on functional carbohydrates
- Application to inflammation in sickle cell disease crisis
- Drug-like properties now in Phase II clinical trials
- Recognition and validation of glycomimetic drugs by the pharmaceutical industry
Talk Citation
Magnani, J. (2012, November 27). Glycobiology: an untapped source of novel drugs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/TTKR2837.Export Citation (RIS)
Publication History
- Published on November 27, 2012
Financial Disclosures
- Dr. John Magnani has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.